Ian Abercrombie joins Medannex as Chief Executive Officer

Medannex is delighted to announce the appointment of Ian Abercrombie as Chief Executive Officer. Ian will be responsible for leading the development of the company’s novel antibody therapies through to the clinical stage.

Ian brings over 25 years’ experience in the pharmaceutical industry, in both clinical development and commercial settings. Over this period Ian has been involved in developing new oncology and haematology therapies, bringing them through clinical development to successful global launch.

Ian has held senior positions in Johnson and Johnson, Bioenvision, Genzyme, Caris Life Sciences and more recently NuCana.

“Now that Medannex has received significant financial backing, we are delighted to have someone of Ian’s experience on board. With a need for rapid expansion, Ian brings exactly the right skills to the company” said Medannex Chairman, Professor Chris Wood. “His operational acumen enhances our ability to exploit the tremendous potential of our technology.”

Ian Abercrombie said, “I am delighted to join Medannex at this important time. The company has very exciting, innovative technology which may modulate the patient’s immune system to treat cancers and autoimmune diseases. I look forward to working with healthcare professionals and other segments of the industry to develop these ground-breaking therapies that may bring something new to offer patients and their families.”